The Centers for Disease Control and Prevention (CDC) and the Agency for Toxic Substances and Disease Registry (ATSDR) released PFAS: Information for Clinicians. This document provides updated information for clinicians to consider when seeing patients who have concerns about per- and polyfluoroalkyl substances (PFAS) exposure or possible health effects.
CDC/ATSDR last updated the PFAS clinician information in 2019. This update incorporates the evolving science and emphasizes the importance of a shared decision-making process, with patients and clinicians working together to address patients’ concerns and reduce PFAS exposures. In order to support discussions with patients, the update provides information for clinicians on exposure sources and routes; health effects associated with PFAS exposures and factors that impact the risk of health effects; considerations for clinical evaluation and management, including information on the benefits and risks of PFAS blood testing; and considerations for certain populations, such as children and those that are pregnant or breastfeeding. CDC/ATSDR also includes links to additional clinical resources and information to assist providers and patients.
More information and the PFAS: Information for Clinicians update can be found at: https://www.atsdr.cdc.gov/pfas/resources/pfas-information-for-clinicians.html. Please share this news with clinicians in your community.
If you have questions, please contact CDC/ATSDR at [email protected].
